Skip to main content
Fig. 5 | BMC Palliative Care

Fig. 5

From: Cost-effectiveness analysis of systematic fast-track transition from oncological treatment to specialised palliative care at home for patients and their caregivers: the DOMUS trial

Fig. 5

Tornado diagrams comparing the relative impact of key assumptions on the estimated ICER on €80,194/QALY. Note: In the period (a) 2013 – June 2015 and (b) 2013–2016. ICER: incremental cost-effectiveness ratio. QALY: quality adjusted life year. Costs include costs of intervention and costs of home nursing and home care. The vertical lines in the two tornado diagrams represent the ICER from the two main cost-effectiveness analyses (€80,194/QALY and €107,213/QALY) to provide a reference the changes in the ICER Source: DOMUS trial data and administrative data from Statistic Denmark and the National eHealth Authority. EQORT for patients’ QALYs

Back to article page

BMC Palliative Care

ISSN: 1472-684X

Contact us